Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.

Objectives: Lenalidomide is a potent drug with pleiotropic effects in patients with myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 5 [del(5q)]. We investigated its effect on regulation of microRNA (miRNA) expression profiles in del(5q) patients with MDS in vivo.

Methods: We used miRNA expression microarrays to study changes in miRNA levels in peripheral blood CD14+ monocytes collected from patients before and during lenalidomide treatment and compared them with those from healthy donors.

DNA repair gene variants are associated with an increased risk of myelodysplastic syndromes in a Czech population.

Background: Interactions between genetic variants and risk factors in myelodysplastic syndromes are poorly understood. In this case-control study, we analyzed 1 421 single nucleotide polymorphisms in 408 genes involved in cancer-related pathways in 198 patients and 292 controls.

Methods: The Illumina SNP Cancer Panel was used for genotyping of samples.